The company will present the results of two
clinical trials that expand the potential health impact of its
flagship 24-strain probiotic and prebiotic, DS-01®
BOSTON, May 20, 2024
/PRNewswire/ -- Seed Health will present new clinical data on
its flagship innovation, DS-01® Daily Synbiotic, a 24-strain
probiotic and prebiotic, at the upcoming 2024 Digestive Disease
Week® (DDW) meeting. The presentations will highlight the results
from two randomized, double-blind, placebo-controlled clinical
trials: one assessing the recovery effects of DS-01® on individuals
during and following antibiotic usage, and another evaluating
DS-01® in patients with irritable bowel syndrome (IBS). The
findings underscore Seed's mission to transform breakthrough
microbiome science into clinically validated consumer health
innovations.
"DS-01® was formulated to maximize genomic diversity and set an
entirely new standard in probiotics," stated Zain Kassam, M.D.,
M.P.H, Chief Medical Officer at Seed Health. "Our latest clinical
data expands DS-01®'s potential health impact, broadens its
clinical use cases, and helps dispel the common perception in the
medical community that all probiotics are created equal."
Dirk Gevers, Ph.D., Chief
Scientific Officer at Seed Health, added, "The findings presented
at DDW highlight the rigorous biopharma approach we bring to
everyday health. We evaluated digestive well-being by studying
biopharmaceutical-type biomarkers, exploring possible mechanisms of
action in IBS, and conducting deeper microbiome sequencing than
typical probiotic trials following antibiotics."
DDW Presentation Highlights
- "Effects of a multi-species synbiotic on microbiome
resilience and gastrointestinal barrier function after antibiotics:
A randomized, double-blind, placebo-controlled clinical
trial."
This clinical trial evaluated the effects of DS-01®
on individuals during and after antibiotic usage. Key findings
include:
- DS-01® significantly improved short-term (25% at Day 7) and
long-term (49% by Day 91) gut barrier integrity during and
following broad-spectrum antibiotics.
- DS-01® restores baseline microbial diversity following
broad-spectrum antibiotics.
- DS-01® significantly enriches both synbiotic and endogenous
beneficial bacteria following broad-spectrum antibiotics.
- "A multi-species synbiotic (DS-01) alleviates irritable
bowel syndrome symptoms while boosting synbiotic consortium: A
randomized, double-blind, placebo-controlled clinical
trial."
This clinical trial assessed the impact of DS-01® in
patients with Irritable Bowel Syndrome (IBS). Key findings include:
- DS-01® led to a significant and clinically meaningful
improvement in abdominal pain among participants with IBS.
- DS-01® led to an enrichment of synbiotic and endogenous
beneficial bacteria.
- DS-01® led to a significant increase in serotonin in IBS-M
participants, a potential mechanism of action.
These presentations will detail the methodology and results from
the two clinical trials which have important implications for the
application of microbiome science in consumer health and
well-being.
Seed's Health clinical data on DS-01® Daily Synbiotic for
antibiotic recovery and IBS will be presented in the session
"Prebiotics, Probiotics and Synbiotics in Health and Disease" on
May 20, 2024, from 12:30 PM to 1:30 PM EDT.
About Seed Health
Seed Health is a microbiome
science company pioneering innovations in probiotics and living
medicines to impact human and planetary health. Founded to realize
the potential of the microbiome, our platform enables the
translation of breakthrough science across a portfolio targeting
health outcomes from infancy to aging. Our consumer innovations are
commercialized under Seed®, an award-winning, science-first
brand known for clinically validated innovations in probiotics,
including DS-01® Daily Synbiotic and PDS-08® Pediatric Daily
Synbiotic. Our pipeline encompasses both indication-specific and
preventive applications for gastrointestinal and digestive health,
women's health, skin, pediatrics, brain health, metabolic function,
and healthy aging. Our environmental research is conducted under
SeedLabs, which was founded to advance novel bacterial
interventions to enhance biodiversity and restore ecosystems
impacted by human activity.
Media Contact
press@seedhealth.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/seed-health-to-present-new-clinical-data-on-ds-01-daily-synbiotic-for-both-antibiotic-recovery-and-ibs-at-digestive-disease-week-2024-302149850.html
SOURCE Seed Health